The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.
Fungal Infectious Diseases or Medical mycology is the study of mycoses and type of physiological situations and environmental are contributing to evolution of fungal diseases. In immune-compromised hosts systemic fungal infections are usually visible because of the inhalation or localization of fungal spores may chronic of systemic fungal infections cause pulmonary infections. Fungal infections are generally seen on skin, nails, and hair. common fungal infections are intertrigo, thrush, and pityriasis versicolor, athlete’s foot, nail infections, ring worm of the frame, ring worm of the groin.
- Track 1-1Classification and Physiology
- Track 1-2Structure and Morphology
- Track 1-3Different types of fungal infections
- Track 1-4Genetic and Biochemical properties
- Track 1-5Mycotoxicology
- Track 1-6Veterinary Mycology
- Track 1-7Environmental Mycology
- Track 1-8Phytomycology
Pathogenic fungi cause disease in humans and in other organisms, which is called as fungal pathogenesis. Fungal pathogens can be divided into two classes primary pathogens and opportunistic pathogens. presently, there has been a dramatic increase in fungal infections of this kind, candidiasis, cryptococcosis, aspergillosis, and zygomycosis. More currently described mycoses of this class include hyalohyphomycosis and phaeohyphomycosis.
- The superficial mycoses -those are superficial fungal infections of the skin or hair shaft.
- Dermatophytosis - ringworm or tinea - ringworm of scalp, glabrous pores and skin, and nails because of an intently associated group of fungi referred to as dermatophytes.
- The subcutaneous mycoses - these are continual, localized infections of the skin and subcutaneous tissue following the worrying implantation of the aetiologic agent.
- Infectious ailment mycology - these are fungal infections of the body because of dimorphic fungal pathogens.
- Track 2-1Aspergillosis and Blastomycosis
- Track 2-2Candidiasis and Candida auris
- Track 2-3Coccidioidomycosis (Valley Fever)
- Track 2-4Talaromycosis and C. neoformans Infection
- Track 2-5Ring worm and Mucormycosis
- Track 2-6Fungal Eye Infections
- Track 2-7Chronic and destructive fungal infections
- Track 2-8Other Fungal Diseases
Opportunistic fungi refers to those fungi that normally would not cause infections in otherwise healthy people but are able to cause infection under certain circumstances such as immune defficiency, cancer, organ transplant, neutropenic patients, diabetes, debilitated patients and patients on long term antibiotics.
Many fungi are opportunists and are usually not pathogenic except in an immunocompromised host. Causes of immunocompromise include AIDS, azotemia, diabetes mellitus, lymphoma, leukemia, other hematologic cancers, burns, and therapy with corticosteroids, immunosuppressants, or antimetabolites. Patients who spend more than several days in an ICU can become compromised because of medical procedures, underlying disorders and undernutrition.
- Track 3-1Types of Opportunistic Fungi
- Track 3-2Filamentous Fungi and Cryptococcosis
- Track 3-3Opportunistic Fungal Pathogens
- Track 3-4Invasive fungal infections
- Track 3-5Subcutaneous Mycoses
- Track 3-6Superficial and Cutaneous Mycoses
- Track 3-7Clinical manifestations and epidemiology
- Track 3-8Immunity and Pathogenesis
- Track 4-1Allergic Bronchopulmonary Aspergillosis
- Track 4-2C. gattii Infection
- Track 4-3Fungal Nail Infections
- Track 4-4Talaromycosis
- Track 4-5Dermatomycoses
- Track 4-6Tinea Versicolor
- Track 4-7scalp infections
- Track 4-8Pathogenesis of Mycosis fungoides
- Track 4-9Subcutaneous Mycoses
- Track 4-10Deep Mycoses
- Track 4-11Mycromycosis
- Track 4-12Dermatophytic reaction
- Track 4-13Contagious skin infection
- Track 4-14Body ring worms
- Track 4-15Derma pathology
Epidemiological patterns that have developed among insusceptible stifled are an expanded rate of obtrusive shape contaminations, for example, aspergillosis. The rising intrusive contagious diseases in the strong organ transplant beneficiaries are candidiasis (53% of all obtrusive parasitic contaminations found) trailed by intrusive aspergillosis (19%), cryptococcosis (8%), non-Aspergillus molds (8%), endemic growths (5%), and zygomycosis (2%).8 There is increment in rate of contaminations brought about by non-albicans Candida species, for example, Candida tropicalis, Candida parapsilosis, and Candida glabrata which are segregated substantially more as often as possible as reasons for intrusive candidiasis worldwide however C. albicans still remains the most widely recognized segregate.
- Track 5-1Root causes of infections
- Track 5-2Invasive Fungal Infections
- Track 5-3Nosocomial Fungal Infections
- Track 5-4Fungal Skin Infections
- Track 5-5Genomic Epidemiology
- Track 5-6Disease Predisposition
The lab analysis gives a scope of demonstrative tests for the discovery and recognizable proof of superficial and invasive fungal infections, including culture, molecules and proteomic strategies, serologic tests, and antifungal susceptibility testing. The defeat of the greater part of these methodologies, as indicated by Pfaller, is that most rely upon the development of fungi in culture, a procedure that is both slow and insensitive.
- Track 6-1Diagnosis of invasive fungal disease (IFD)
- Track 6-2Histopathology Techniques
- Track 6-3Serologic tests
- Track 6-4Microscopic Examination
- Track 6-5Non-Culture-Based Molecular Diagnostic Methods
- Track 6-6Culture-Based Molecular Diagnostic Methods
- Track 6-7Molecular and Nonmolecular Diagnostic Methods
- Track 6-8New strategies for rapid detection of fungal infections
An antifungal medication is a pharmaceutical fungicide or fungi static used to treat and prevent mycoses, which are most commonly found on the skin, hair and nails. It works by exploiting differences between mammalian and fungal cells to kill the fungal organism with fewer adverse effects to the host. Antifungal medicines are used in several ways, depending on the specific fungal infection. The main types of antifungal medicines include, topical antifungals, oral antifungals, intravenous antifungals, intracranial antifungal pessaries etc.
- Track 7-1Anti Fungal Drugs
- Track 7-2Mechanisms of Antifungal Resistance
- Track 7-3Drug Combinations
- Track 7-4Antifungal Immunotherapy
- Track 7-5Pharmacology
- Track 7-6Antifungal drugs and Side effects
- Track 7-7Antifungal medicines for children
- Track 7-8Natural treatment Methods
- Track 7-9Preventive measures
Fungi occur in all type of environment on earth and plays vital roles in most ecosystems. These are the major decomposers along with bacteria in most terrestrial and some aquatic ecosystems, and therefore play a critical role in biogeochemical cycles and in many food webs play an essential role in nutrient cycling by degrading organic matters to inorganic molecules, which can then re-enter to different anabolic metabolic pathways in plants and other organisms.
- Track 8-1Population dynamics, adaptation and evolution
- Track 8-2Role in ecosystem functioning
- Track 8-3Nutrient cycling, decomposition and carbon allocation
- Track 8-4Eco-physiology
- Track 8-5Intra- and inter-specific mycelial interactions
- Track 8-6Fungus-plant (pathogens, mycorrhizas, lichens, endophytes)
- Track 8-7Fungus-invertebrate and fungus-microbe interaction
- Track 8-8Genomics and (evolutionary) genetics
Most industrial Processes used fungal cells for the major production of organic acids, proteins, enzymes, secondary metabolites and lively pharmaceutical substances in white and red biotechnology. A number of challenges now need to be addressed to improve our techniques to control fungal pathogenicity and to optimise using fungi as sources for novel compounds. In addition to the multiple response sequences of fermentations, fungi are extremly useful in the biotransformation processes. Molecular manipulations had been added to mutational strategies as a method of increasing yields of microbial processes and in the discovery of new drugs.
- Track 9-1Recombinent DNA technology
- Track 9-2RNA Interferance technology
- Track 9-3Recent research in Scedosporium prolificans
- Track 9-4Challenges in identification
- Track 9-5Fungal metabolites
- Track 9-6Fungal Genomics
The fungi that are responsible for causing diseases in humans, animals and plants are referred to as Pathogenic fungi. Many of pathogenic fungi are naked in nature although they are eukaryotic. Candida species, Aspergillus species, Cryptococcus species, Histoplasma species are pathogenic in nature.
Fungal diseases have contributed to death and disability in humans, triggered global wildlife extinctions and population declines, devastated agricultural crops, and altered forest ecosystem dynamics.
The past two decades have seen an increasing number of virulent infectious diseases in natural populations and managed landscapes. In both animals and plants, an unprecedented number of fungal and fungal-like diseases have recently caused some of the most severe die-offs and extinctions ever witnessed in wild species, and are jeopardizing food security. Human activity is intensifying fungal disease dispersal by modifying natural environments and thus creating new opportunities for evolution. We argue that nascent fungal infections will cause increasing attrition of biodiversity, with wider implications for human and ecosystem health, unless steps are taken to tighten biosecurity worldwide.
- Track 10-1Increasing risk of biodiversity loss by Fungi
- Track 10-2Mechanisms of disease-induced extinction
- Track 10-3Fungal pathogens
- Track 10-4Fungal infections
- Track 10-5Factor of Emergence
- Track 10-6Discovery and Spread
- Track 10-7Phenomenology
- Track 10-8Amphibian Chytridiomycosis
- Track 10-9Predictive Modeling
Filamentous fungi are used by industry for manufacture of a large variety of useful products. The products include metabolites, enzymes and food. Fungal cells can grow at different environmental conditions and environmental diversity. The chemical and physical conditions used for fungal propagation which depends up on fungal genetics and biology will have a great impact on the capability of these cells to accumulate the desired product(s). Mevinolin, cyclosporine A, β-lactam antibiotics, pneumocandins, ergotamine, strobilurins, and mycophenolic acid are examples of revolutionary pharmaceuticals and agrochemicals that have a fungal origin in spite of the success of bioactive fungal metabolites as pharmaceuticals and agrochemicals and fungi remain s an essentially untapped source of medicines because only a small fraction of the vast fungal kingdom has been explored for bioactive metabolite production. However, recent advances in the genetics of microbial secondary metabolite biosynthesis, genomics, and metabolic engineering will play an ever-increasing role in facilitating fungal bioactive metabolites discovery.
- Track 11-1Food and Beverages Industry
- Track 11-2Antibiotics â€“ Penicillin
- Track 11-3Immuno-suppressive
- Track 11-4Fungi in waste treatment
- Track 11-5Mycodiesel
- Track 11-6Baking Industry
- Track 11-7Immuno-suppressive
Edible mushrooms are the fleshy fruit bodies of several species of macro-fungi. They can appear either below ground or above ground where they may be picked by hand. Edibility may be defined by criteria that include the absence of poisonous effects on humans and desirable taste and aroma. Mushrooms play extremely important roles in the ecosystem, and some are famously delicious. Some are also famously deadly. In recent years has focused on various immunological and anti-cancer properties of certain mushrooms, they also offer other potentially important health benefits, including antioxidants, anti-hypertensive and cholesterol-lowering properties, liver protection, as well as anti-inflammatory, anti-diabetic, anti-viral and anti-microbial properties. These properties have attracted the interest of many pharmaceutical companies, which are viewing the medicinal mushroom as a rich source of innovative biomedical molecules. Mushrooms contain disease-busting polysaccharides, glycoproteins, ergosterols, triterpenoids, and immune-boosting chemicals. They can also be used to bolster a declining immune system during aging.
- Track 12-1Medicinal Mushrooms
- Track 12-2Anticancer Activity
- Track 12-3Mechanism of Modulating the Immune System
- Track 12-4Effects of Mushrooms
- Track 12-5Cancer-fighting ingredients
- Track 13-1Applied Mycology
- Track 13-2Fungal Biotechnology (Mycotechnology)
- Track 13-3Marine Mycotechnology and biodiversity
- Track 13-4Fungal bioactive metabolites
- Track 13-5Environmental mycology
- Track 13-6Fungal pesticides and biological control